The use of exogenous creatine phosphate for myocardial protection in patients undergoing coronary artery bypass surgery a clinical assessment

Journal of Cardiovascular Surgery

Volumn 37, Issue 6 SUPPL. 1, 1996, Pages 75-80

  Cisowski, M ^a   Bochenek, A ^a   Kucewicz, E ^a   Wnuk Wojnar, A M ^a   Morawski, W ^a   Skalski, J ^a   Grzybek, H ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cardioplegic solutions; Creatine phosphate

Indexed keywords

BICARBONATE; CALCIUM CHLORIDE; CARDIOPLEGIC AGENT; CARDIOTONIC AGENT; CREATINE PHOSPHATE; MAGNESIUM; POTASSIUM CHLORIDE; SODIUM CHLORIDE; ST. THOMAS' HOSPITAL CARDIOPLEGIC SOLUTION;

ARTICLE; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEART ARREST; HUMAN; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY;

BICARBONATES; CALCIUM CHLORIDE; CARDIOPLEGIC SOLUTIONS; CARDIOTONIC AGENTS; CORONARY ARTERY BYPASS; FEMALE; HEART ARREST, INDUCED; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; PHOSPHOCREATINE; POTASSIUM CHLORIDE; SODIUM CHLORIDE;

EID: 0030308162     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Reimer KA, Jennings RB, Tatum AH. Am J Cardiol 1983;52:72-81.
2. Reimer KA, Jennings RB, Hill ML. Circ Res 1981;49:901-11.
3. Chambers DJ, Braimbridge MV, Kosker S et al. Creatine phosphate (Neoton) as an additive to St. Thomas' Hospital cardioplegic solution. Eur J Cardio Thorac Surg 1991;5:74-81.
4. Robinson LA, Braimbridge MV, Hearse DJ. Enhanced myocardial protection with high energy phosphates in St. Thomas' Cardioplegic Solution: Synergism of adenosine triphosphate and creatine phosphate. J Thorac Cardiovasc Surg 1987;93:415-27.
5. Robinson LA, Braimbridge MV, Hearse DJ. Creatine phosphate: An additive myocardial protective and anti-arrhythmic agent in cardioplegia. J Thorac Cardiovasc Surg 1984;87:190-200.
6. Sharov VG, Saks VA, Kuprianov W, Lakomin VL, Kapelko VI, Steinschneider AY, Javadov SA. Protection of ischemic myocardium by exogenous phosphocreatine. I. Morphologic and phosphorus 31 nuclear magnetic resonance studies. J Thorac Cardiovasc Surg 1987;94:749-61.
7. Semenovsky ML, Shumakov VI, Sharov VG et al. Protection of ischemic myocardium by exogenous phosphocreatine. II. Clinical, ultrastructural and biochemical evaluations. J Thorac Cardiovasc Surg 1987;94:762-9.
8. Tranconi L, Raisaro A, Pagani L et al. Creatine phosphate and myocardial protection: experience in cardiosurgery. In: Saks VA, Bobkov YG, Strumia E. Creatine phosphate-biochemistry, pharmacology and clinical efficiency. Torino: Edizioni Minerva Medica, 1987:242-50.
9. Ravel JP, Karnovsky MJ. Hexagonal array of subunits in intercellular junction of the mouse heart and liver. J Cell Biol 1967;33:C7-C12.
10. Degenring FH, Curnish RR, Rubio R, Berne RM. Effect of dipirydamole on myocardial adenosine metabolism and coronary flow in hypoxia and reactive hypotermia in the isolated perfused guinea pig heart. J Mol Cell Cardiol 1976;8:877-88.
11. Foker JE, Einzig S, Wang T. Adenosine metabolism and myocardial preservation. J Thorac Cardiovasc Surg 1980;80:506-16.
12. Swain JL, Hines JJ, Sabina RL, Holmes EW. Circ Res 1982; 51:102-5.
13. Jennings RB, Hawkins HK, Lowe JE et al. Relation between high energy phosphate and lethal injury in myocardial ischemia in the dog. Am J Pathol 1978;92:187-207.
14. Hearse DJ, Tanaka K, Crome R, Manning AS. Creatine phosphate and protection against reperfusion induced arrhythmias in the rat heart. Eur J Pharmacol 1986;131:21-30.
15. Marshall RJ., Parrat JR. Reduction of ventricular arrhythmias following acute coronary artery ligation in the dog after administration of creatine phosphate. Naunyn-Schmiedeberg's Arch Pharmacol 1974;281:437-41.
16. Parrat JR, Marshall RJ. The response of isolated cardiac muscle to acute anoxia: protective effect of adenosine triphosphate and creatine phosphate. J Pharm Pharmai 1974;26:427-33.
17. Saks VA, Sharov VG, Kupriyanov W et al. Phosphocreatine and related compounds: Protective myocardium. Myocardial metabolism-cardiovascular review. London: Harwood Academic Publ, 1987;Suppl 2:446-80.
18. Saks VA, Javadov SA, Pozin E Preobrazhensky AM. Biochemical basis of the protective action of phosphocreatine on the ischemic myocardium. In: Sacs Va, Bobkov YG, Strumia E, editors. Proceedings of the Symposium "Creatine-phosphate: Biochemistry, Pharmocology and Chemical Efficiency", Baku, October 6, 1986. Torino: Minerva Med Ed., 1987:95.
19. Sharov VG, Afonskaya N, Ruda MY et al. Protection of ischemic myocardium by exogenous phosphocreatine (Neoton); Pharmacokinetics of phosphocreatine reduction in infarct size, stabilization of sarcolemma of ischemic cardiomyocytes and antithrombotic action. Biochem Med Metab Biol 1986;35:101-14.
20. Zucchi R, Poddighe R, Limbruno U et al. Protection of isolated rat heart from oxidative stress by exogenous CP. J Mol Cell Cardiol 1989;21:67-73.
21. Saks VA, Rosenshtraukh CV, Smirnov UN, Chazov EI. Role of creatine phosphokinase in cellular function and metabolism. Can J Physiol Pharmacol 1978;56:691-706.
22. Baur HR, Steele BW, Preimsberger KF, Gobel FL. Serum myocardial creatine kinase (CK-MB) after coronary arterial bypass surgery. Am J Cardiol 1979;44:679-86.